These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36934836)

  • 1. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
    Wang Z; Wu B; Nie G; Wei J; Li Y
    Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting pancreatic cancer metabolism: challenges and opportunities.
    De Santis MC; Bockorny B; Hirsch E; Cappello P; Martini M
    Trends Mol Med; 2024 Jun; 30(6):592-604. PubMed ID: 38604929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer.
    Ohara Y; Valenzuela P; Hussain SP
    Trends Cancer; 2022 Jul; 8(7):556-569. PubMed ID: 35525794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma.
    Ni B; Yin Y; Li Z; Wang J; Wang X; Wang K
    Neurosci Bull; 2023 Nov; 39(11):1717-1731. PubMed ID: 37347365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
    Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
    Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
    Liu YH; Hu CM; Hsu YS; Lee WH
    Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cancer cell metabolism in pancreatic adenocarcinoma.
    Cohen R; Neuzillet C; Tijeras-Raballand A; Faivre S; de Gramont A; Raymond E
    Oncotarget; 2015 Jul; 6(19):16832-47. PubMed ID: 26164081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Review of Metabolic Stress and Development of Pancreatic Cancer].
    Li JT; Lei MZ; Lei QY; Yin M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jan; 52(1):5-10. PubMed ID: 33474881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.
    Hartupee C; Nagalo BM; Chabu CY; Tesfay MZ; Coleman-Barnett J; West JT; Moaven O
    Front Immunol; 2024; 15():1287459. PubMed ID: 38361931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze.
    Olivares O; Vasseur S
    Int J Cancer; 2016 Feb; 138(4):787-96. PubMed ID: 25732227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
    Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
    Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.
    Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E
    Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness.
    Rademaker G; Hennequière V; Brohée L; Nokin MJ; Lovinfosse P; Durieux F; Gofflot S; Bellier J; Costanza B; Herfs M; Peiffer R; Bettendorff L; Deroanne C; Thiry M; Delvenne P; Hustinx R; Bellahcène A; Castronovo V; Peulen O
    Oncogene; 2018 Aug; 37(32):4398-4412. PubMed ID: 29720728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment.
    Wong CW; Han HW; Tien YW; Hsu SH
    Biomaterials; 2019 Aug; 213():119202. PubMed ID: 31132644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma.
    Xu B; Chen Y; Peng M; Zheng JH; Zuo C
    Int J Cancer; 2023 Jan; 152(2):110-122. PubMed ID: 35765844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.